Nithya Balasubramanian on why Cipla will outperform its peers and market post FY23
“In trade generics, Cipla traditionally has been a market leader and I believe that in the next three-four years, trade generics will continue to grow faster than the market and given that they are market leaders with established equity in the system and distribution muscle, I expect Cipla to grow faster.”